2022 American Transplant Congress
Alloreactive Regulatory T Cells Release Distinct Subpopulations of Extracellular Vesicles Bearing Immune Regulatory Proteins and the TCR/CD3 Complex Under Antigen Specific Stimulation
Brigham and Women's Hospital, Boston, MA
*Purpose: Extracellular vesicles (EVs) are vital mediators of intercellular communication, playing an important role in the immune synapse and the T cell response. However, regulatory…2022 American Transplant Congress
Use of Dd-cfdna to Guide Tapering of Immunosuppression Therapy in Kidney Transplant Recipients
1Victoria Kidney and Dialysis Associates, Victoria, TX, 2Natera, Inc., Austin, TX
*Purpose: Continuous administration of immunosuppressive therapy (IST) is required to avoid allograft rejection in transplant recipients. However, these therapeutic interventions can lead to significant side…2022 American Transplant Congress
Conversion from Immediate to Extended-Release Tacrolimus (LCP-Tac) Six Months After Renal Transplantation Optimizes Safety and Efficacy
*Purpose: LCP-Tac is a once daily formulation of tacrolimus indicated for prevention of rejection in kidney transplant recipients (KTRs) that may have less variability and…2022 American Transplant Congress
Low Fixed Tacrolimus Starting Dose and the Correlation with Renal Allograft Rejection
David Geffen School of Medicine, Los Angeles, CA
*Purpose: Achieving a tacrolimus therapeutic trough concentration (C0) by post-operative day (POD) 3-7 has been associated with a reduced risk for rejection. Although FDA prescribing…2022 American Transplant Congress
Real World Experience Utilizing Donor Kidneys at Risk for Acute Kidney Injury with Belatacept Based Maintenance Immunosuppression
University of Utah Health, Salt Lake City, UT
*Purpose: The demand for kidney transplant continues to rise, and limited supply has encouraged acceptance of marginal donor organs, such as those at risk for…2022 American Transplant Congress
Patient Reported Outcomes Following Renal Transplantation: The Future of Holistic Post-Transplant Care
*Purpose: Patients with renal disease prioritise symptoms and functionality over the biochemistry and clinical guidelines, which clinicians traditionally rely on. Whilst kidney transplantation is expected…2022 American Transplant Congress
Acute Tubular Injury and Necrosis Do Not Lead to Meaningful Elevations in Donor-Derived Cell-Free DNA (dd-cfDNA)
*Purpose: Associations between non-rejection histologic diagnoses and dd-cfDNA have not been extensively characterized. We explored these associations in kidney transplant recipients enrolled in the Kidney…2022 American Transplant Congress
Real-Life Prevention of Breakthrough SARS-CoV-2 Infections by mRNA Vaccines in Kidney Transplant Recipients vs Hemodialysis Patients
Nephrology and Renal Transplantation, Hospital Clinic of Barcelona, Barcelona, Spain
*Purpose: The increased COVID-19 severity observed in kidney transplant recipients (KTR) has been widely reported. In addition, several studies have shown a reduced humoral and…2022 American Transplant Congress
Kinetics of dd-cfDNA in Kidney Transplant Recipients Following Sars-CoV-2 Vaccination Booster Administration
1Transplant Institute, NYU Langone Health, New York, NY, 2CareDx, Brisbane, CA
*Purpose: Evolving data suggests booster vaccine doses enhance the immunogenicity of SARS-CoV-2 vaccines in solid organ transplant recipients with higher IgG responses, neutralizing antibodies titers,…2022 American Transplant Congress
A Single-Center Cross-Sectional Analysis of Lipid Management in Kidney Transplant Recipients: Is It Time to Reassess KDIGO Guidelines?
1Renal Division, Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA
*Purpose: Cardiovascular disease remains the leading cause of mortality after kidney transplant, accounting for more than 30% of total deaths. Dyslipidemia is common following transplantation,…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 531
- Next Page »